Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, but adjusted profits excluding exceptions ...

Sun Pharmaceutical's shares fell 5.7% to ₹1,608.30 after a 20% drop in net profit to ₹2,278 crore for Q1 FY26. Despite this, revenue grew 9% to ₹13,851 crore, supported by strong performances in key ...

Choice Broking maintained an ‘ADD’ rating and a target price of Rs 1,825 on Sun Pharma. At the prevailing price, the target ...

Sun Pharma stock fell as much as 5.78% during trade so far to Rs 1,608 apiece on the NSE. It was trading 3.65% lower at Rs ...

Sun Pharmaceutical, India's largest drug maker, is not planning to expand its manufacturing base in the US, citing sufficient ...

Sun Pharmaceutical Industries reported a decline of 20 per cent in net profit at Rs. 2,278.63 crore during the first quarter of the current fiscal year, as compared to Rs. 2,835.62 crore during the ...

Healthy double-digit growth in its India business and innovative medicines pipeline boosted its revenue and Ebitda margins ...

Stocks to Buy Today Recommendations, August 1, 2025: Brokerages have recommended several stocks to buy today (August 1) for long-term gains. The top recommendations are- HUL, IGL, Sun Pharma and ...

Sun Pharma's Q1 net profit fell 20% YoY to Rs 2,279 crore, while adjusted net profit rose 6%. India market showed strong momentum. Leqselvi US launch announced.

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, standing at ₹2,279 crore. The fall is ...

Sun Pharma posted a 20% YoY drop in Q1 net profit at Rs 2,278 crore. However, revenue rose 10% to Rs 13,786 crore, with improved EBITDA margins. Brokerages remain divided on the stock, citing ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...